2002
DOI: 10.1016/s0301-472x(02)00820-2
|View full text |Cite
|
Sign up to set email alerts
|

Mesenchymal stem cells promote engraftment of human umbilical cord blood–derived CD34+ cells in NOD/SCID mice

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

6
317
4
10

Year Published

2006
2006
2016
2016

Publication Types

Select...
4
3

Relationship

0
7

Authors

Journals

citations
Cited by 448 publications
(337 citation statements)
references
References 34 publications
6
317
4
10
Order By: Relevance
“…The enhancing effect involved cells of myeloid, lymphoid and megakaryocytic lineages, with this finding showing that the engraftmentpromoting effect of MSCs was not lineage specific and it was particularly prominent when the dose of HSCs was low. 28,43 Altogether, these data suggest that co-infusion of MSCs could be a promising strategy to optimize the engraftment of UCB progenitors, especially in the presence of HLA disparities between the donor and the recipient, and have provided the rationale for testing the capacity of these cells to facilitate hematological recovery in human patients given allogeneic UCBT.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…The enhancing effect involved cells of myeloid, lymphoid and megakaryocytic lineages, with this finding showing that the engraftmentpromoting effect of MSCs was not lineage specific and it was particularly prominent when the dose of HSCs was low. 28,43 Altogether, these data suggest that co-infusion of MSCs could be a promising strategy to optimize the engraftment of UCB progenitors, especially in the presence of HLA disparities between the donor and the recipient, and have provided the rationale for testing the capacity of these cells to facilitate hematological recovery in human patients given allogeneic UCBT.…”
Section: Discussionmentioning
confidence: 99%
“…Ten study patients are alive, at a median follow-up of 28 months (range [19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38]; in the control group, 25 patients are alive with a median follow-up of 42 months (range 16-134). The Kaplan-Meier estimate of OS at 3 years is 63% (95% CI 43-97) and 64% (95% CI 48-79; P ¼ NS) in study patients and controls, respectively.…”
Section: Os Efs and Leukemia-free Survivalmentioning
confidence: 99%
See 1 more Smart Citation
“…On the other hand, the MSC capability of facilitating the engraftment of transplanted HSC has been investigated in more detail [11,66]. In a non-human primate model of organ transplantation, MSC delayed the T cell-mediated rejection of skin allografts [12].…”
Section: Msc-mediated Immunological Effects In Vivomentioning
confidence: 99%
“…As a consequence, MSC hold promise not only for improving HSC engraftment upon allogeneic transplantation [11], but also for repairing damaged tissues. However, while MSC are naturally prone to differentiate into cells of mesodermal origin, their capacity of transdifferentiating in vivo is still debated and it is likely to be of limited biological relevance.…”
Section: Introductionmentioning
confidence: 99%